KalVista Pharmaceuticals, Inc. (KALV) is a publicly traded company in the Unknown sector. Across all available filings, 28 corporate insiders have executed 435 transactions totaling $146.0M, demonstrating a bearish sentiment with -$28.8M in net insider flow. The most recent transaction on Feb 23, 2026 involved a sale of 1,767 shares valued at $27.5K.
No significant insider buying has been recorded for KALV in the recent period.
No significant insider selling has been recorded for KALV in the recent period.
Based on recent SEC filings, insider sentiment for KALV is bearish with an Insider Alignment Score of 40/100 and a net flow of -$28.8M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at KalVista Pharmaceuticals, Inc. (KALV) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 28 insiders are actively trading KALV stock, having executed 435 transactions in the past 90 days. The most active insider is Holdings A/s Novo (Executive), who has made 16 transactions totaling $28.8M.
Get notified when executives and directors at KALV file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | Piekos Brian | Chief Financial Officer | Sale | 1,767 | $15.57 | $27.5K | C-Suite |
| Feb 23, 2026 | Sweeny Nicole | Chief Commercial Officer | Sale | 3,975 | $15.57 | $61.9K | |
| Feb 23, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sale | 4,347 | $15.57 | $67.7K | |
| Feb 23, 2026 | L. Palleiko Benjamin | Executive | Sale | 10,034 | $15.57 | $156.2K | |
| Feb 23, 2026 | K. Audhya Paul | CHIEF MEDICAL OFFICER | Sale | 5,354 | $15.57 | $83.3K | |
| Feb 22, 2026 | Sweeny Nicole | Chief Commercial Officer | Option Exercise | 5,000 | $N/A | $0 | |
| Feb 22, 2026 | Sweeny Nicole | Chief Commercial Officer | Option Exercise | 5,000 | $N/A | $0 | |
| Feb 22, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Option Exercise | 3,125 | $N/A | $0 | |
| Feb 22, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Option Exercise | 3,125 | $N/A | $0 | |
| Feb 22, 2026 | K. Audhya Paul | CHIEF MEDICAL OFFICER | Option Exercise | 5,000 | $N/A | $0 | |
| Feb 22, 2026 | K. Audhya Paul | CHIEF MEDICAL OFFICER | Option Exercise | 5,000 | $N/A | $0 | |
| Feb 21, 2026 | Piekos Brian | Chief Financial Officer | Option Exercise | 5,000 | $N/A | $0 | C-Suite |
| Feb 21, 2026 | Piekos Brian | Chief Financial Officer | Option Exercise | 5,000 | $N/A | $0 | C-Suite |
| Feb 21, 2026 | Sweeny Nicole | Chief Commercial Officer | Option Exercise | 6,250 | $N/A | $0 | |
| Feb 21, 2026 | Sweeny Nicole | Chief Commercial Officer | Option Exercise | 6,250 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 247 | $87.4M | 59.1% |
Purchase(P) | 40 | $58.6M | 39.6% |
Exercise(M) | 119 | $1.9M | 1.3% |
Payment(F) | 1 | $42.6K | 0.0% |
Award(A) | 23 | $0 | 0.0% |
Gift(G) | 5 | $0 | 0.0% |
Insider activity at KalVista Pharmaceuticals, Inc. shows mixed signals across all time. While $58.6M in purchases indicates some executive confidence,$87.4M in sales balances the picture, resulting in a modest net flow of -$28.8M.28 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Holdings A/s Novo, has transacted $28.8M during this period.